McGovern Susan L, Liao Zhongxing, Bucci M Kara, McAleer Mary Frances, Jeter Melenda D, Chang Joe Y, O'Reilly Michael S, Cox James D, Allen Pamela K, Komaki Ritsuko
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Cancer. 2009 Jul 15;115(14):3233-42. doi: 10.1002/cncr.24361.
Lung cancer is the leading cause of cancer death for both men and women, but the disease course differs between the sexes. To the authors' knowledge, sex-based differences in outcomes among the population of nonsmall cell lung cancer (NSCLC) patients receiving radiation have not been well defined.
Data for 831 patients (319 women and 512 men) with stage I to III NSCLC and treated with > or =45 Gray of radiation between March 1985 and November 2003 were retrospectively analyzed (grading determined according to the 1997 American Joint Committee on Cancer grading system).
Women were more likely to have earlier stage disease, to have smoked <50 pack-years, and to have adenocarcinoma or large-cell carcinoma (all P < or = .001). For each stage, treatment did not differ between women and men. Five-year survival rates were significantly better for women than for men: overall survival (OS), 28.6% versus 16.1% (P < .001); disease-free survival, 31.2% versus 20.1% (P = .02); and distant metastasis-free survival, 48.8% versus 37.6% (P < .02). Among patients with medically inoperable stage I NSCLC, women had improved 5-year OS compared with men (30.0% vs 13.1%; P = .004). On multivariate analysis, male sex, weight loss, age > or =65 years, and stage III disease were found to be associated with poorer OS (all P < 0.02).
Although women are more likely to have earlier stage disease, among patients with medically inoperable stage I NSCLC, women still have a better OS. Along with known prognostic factors, including age, weight loss, and stage, sex remained significant on multivariate analysis of OS, suggesting that sex is a determinant of outcome in NSCLC patients receiving radiation.
肺癌是男性和女性癌症死亡的主要原因,但两性的病程有所不同。据作者所知,接受放疗的非小细胞肺癌(NSCLC)患者人群中基于性别的预后差异尚未明确界定。
回顾性分析了1985年3月至2003年11月期间831例I至III期NSCLC患者(319例女性和512例男性)的数据,这些患者接受了≥45格雷的放疗(分级根据1997年美国癌症联合委员会分级系统确定)。
女性更有可能患有早期疾病、吸烟<50包年,且患有腺癌或大细胞癌(所有P≤0.001)。对于每个阶段,女性和男性的治疗无差异。女性的5年生存率显著高于男性:总生存率(OS),28.6%对16.1%(P<0.001);无病生存率,31.2%对20.1%(P=0.02);远处转移无进展生存率,48.8%对37.6%(P<0.02)。在医学上无法手术的I期NSCLC患者中,女性的5年OS较男性有所改善(30.0%对13.1%;P=0.004)。多变量分析显示,男性、体重减轻、年龄≥65岁和III期疾病与较差的OS相关(所有P<0.02)。
虽然女性更有可能患有早期疾病,但在医学上无法手术的I期NSCLC患者中,女性仍有较好的OS。除年龄(岁)、体重减轻和分期等已知预后因素外,性别在OS多变量分析中仍然显著,这表明性别是接受放疗的NSCLC患者预后的一个决定因素。